Salubris Pharma's YOLT-101 clinical trial application accepted

Shenzhen Salubris Pharmaceuticals (SZSE:002294) announced that the National Medical Products Administration has accepted its clinical trial application for YOLT-101, a gene-editing drug targeting PCSK9. The drug, licensed from Yaotang (Shanghai) Biotechnology, is intended for treating familial hypercholesterolemia by reducing LDL-C levels. YOLT-101 works by editing the PCSK9 gene, potentially offering a more convenient treatment option compared to existing therapies. Salubris emphasized that the drug's development is subject to risks inherent in pharmaceutical research and that the acceptance does not guarantee clinical trial success or market approval. Further updates will be disclosed as required.